Disopyramide phosphate | CAS#22059-60-5

MedKoo Cat#: 317629 | Name: Disopyramide phosphate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Disopyramide is an antiarrhythmic medication used in the treatment of Ventricular Tachycardia. It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility.

Chemical Structure

Disopyramide phosphate

CAS#22059-60-5 (phosphate)

Theoretical Analysis

MedKoo Cat#: 317629

Name: Disopyramide phosphate

CAS#: 22059-60-5 (phosphate)

Chemical Formula: C21H32N3O5P

Exact Mass: 0.0000

Molecular Weight: 437.47

Elemental Analysis: C, 57.66; H, 7.37; N, 9.61; O, 18.29; P, 7.08

Price and Availability

Size	Price	Availability	Quantity
5g	USD 950.00	2 Weeks
10g	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

3737-09-5 (free base) 22059-60-5 (phosphate) 54687-36-4 (HCl)

Synonym

SC 13957; SC-13957; SC13957; Disopyramide phosphate; trade names Norpace and Rythmodan.

IUPAC/Chemical Name

4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide phosphate

InChi Key

CGDDQFMPGMYYQP-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H29N3O.H3O4P/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19;1-5(2,3)4/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25);(H3,1,2,3,4)

SMILES Code

O=C(N)C(C1=CC=CC=C1)(CCN(C(C)C)C(C)C)C2=NC=CC=C2.O=P(O)(O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#M9S07K24

QC Data

View QC data: current batch, Lot#M9S07K24

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 437.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Anzawa R, Ishikawa S, Tanaka Y, Okazaki F, Mochizuki S. Increased AAI mode pacing threshold after termination of atrial fibrillation by acute administration of disopyramide phosphate. Europace. 2006 May;8(5):345-8. PubMed PMID: 16635993. 2: Anzawa R, Ishikawa S, Tanaka Y, Okazaki F, Mochizuki S. Atrial pacing failure following termination of atrial fibrillation by acute administration of disopyramide phosphate. J Interv Card Electrophysiol. 2005 Jun;13(1):51-3. PubMed PMID: 15976979. 3: Tsuchioka Y, Nakagawa H, Yamagata T, Sakura E, Hashimoto M, Okamoto M, Matsuura H, Kajiyama G. [Effects of verapamil and disopyramide phosphate on the termination, reinduction and long-term prevention of paroxysmal supraventricular tachycardia]. Kokyu To Junkan. 1990 Mar;38(3):243-8. Japanese. PubMed PMID: 2109870. 4: Means JR, Hjelle JJ, Kotsonis FN. The effects of disopyramide phosphate on serum glucose and glucose counterregulation in the dog. Fundam Appl Toxicol. 1985 Jun;5(3):539-45. PubMed PMID: 3891480. 5: Swezey CB, Ponzo JL. Determination of disopyramide phosphate in serum by high-performance liquid chromatography. Ther Drug Monit. 1984;6(2):211-4. PubMed PMID: 6429911. 6: Tajima T, Dohi Y. The effect of disopyramide phosphate on ventricular fibrillation threshold of normal and ischemic ventricles. Jpn Heart J. 1983 Nov;24(6):985-93. PubMed PMID: 6423856. 7: Arif M, Laidlaw JC, Oshrain C, Willis PW 3rd, Nissen CH, McDermott DJ, Smith WS, Karim A, Wilson RR. A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias. Angiology. 1983 Jun;34(6):393-400. PubMed PMID: 6408949. 8: Fechter P, Ha HR, Follath F, Nager F. The antiarrhythmic effects of controlled release disopyramide phosphate and long acting propranolol in patients with ventricular arrhythmias. Eur J Clin Pharmacol. 1983;25(6):729-34. PubMed PMID: 6662171. 9: Bexton RS, Hellestrand KJ, Cory-Pearce R, Spurrell RA, English TA, Camm AJ. The direct electrophysiologic effects of disopyramide phosphate in the transplanted human heart. Circulation. 1983 Jan;67(1):38-45. PubMed PMID: 6401173. 10: Kowey PR, Friedman PL, Podrid PJ, Zielonka J, Lown B, Wynne J, Holman BL. Use of radionuclide ventriculography for assessment of changes in myocardial performance induced by disopyramide phosphate. Am Heart J. 1982 Oct;104(4 Pt 1):769-74. PubMed PMID: 6812403. 11: Kumana CR, Rambihar VS, Tanser PH, Cairns JA, Gupta RN, Wildeman RA, Johnston M, Johnson AL, Gent M. A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction. Br J Clin Pharmacol. 1982 Oct;14(4):519-27. PubMed PMID: 6753887; PubMed Central PMCID: PMC1427600. 12: Katoh T, Sasaki Y, Tsuda T. [Effects of disopyramide phosphate in repetitive paroxysmal ventricular tachycardia]. Kokyu To Junkan. 1982 Sep;30(9):959-64. Japanese. PubMed PMID: 7178700. 13: Tajima T, Dohi Y. Electrophysiological effects of intravenous disopyramide phosphate on the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol. 1982 Sep;5(5):741-7. PubMed PMID: 6182545. 14: Hori Y, Okamoto R, Hatani M, Imai N, Toh H, Takano S, Nadai T, Fukuzaki H. Studies on the preventive method of lowered ventricular fibrillation threshold during experimental acute myocardial infarctions. A comparison between disopyramide phosphate and lidocaine. Jpn Heart J. 1981 Sep;22(5):801-13. PubMed PMID: 7321204. 15: Satoh M, Sada T, Kuan-Min S, Kira Y, Sekine I, Okabe F, Ueda A, Ito T, Matsumoto S. [Antiarrhythmic actions of disopyramide phosphate in patients with paroxysmal supraventricular tachycardia (author's transl)]. Kokyu To Junkan. 1981 May;29(5):537-44. Japanese. PubMed PMID: 7313358. 16: Wilcox RG. Acute intervention studies in patients with myocardial infarction using atenolol, propranolol, oxprenolol and disopyramide phosphate. Acta Med Scand Suppl. 1981;651:193-202. PubMed PMID: 6119875. 17: Camm J, Ward D, Spurrell R. Response of atrial flutter to overdrive atrial pacing and intravenous disopyramide phosphate, singly and in combination. Br Heart J. 1980 Sep;44(3):240-7. PubMed PMID: 7426181; PubMed Central PMCID: PMC482392. 18: Sinatra ST, Landry AB Jr, Galle JS, Amato J. Cardiogenic shock associated with disopyramide phosphate. JAMA. 1980 Mar 21;243(11):1132. PubMed PMID: 7359659. 19: Story JR, Abdulla AM, Frank MJ. Cardiogenic shock and disopyramide phosphate. JAMA. 1979 Aug 17;242(7):654-5. PubMed PMID: 449005. 20: Camm J, Ward D, Washington HG, Spurrell RA. Intravenous disopyramide phosphate and ventricular overdrive pacing in the termination of paroxysmal ventricular tachycardia. Pacing Clin Electrophysiol. 1979 Jul;2(4):395-402. PubMed PMID: 95308.